@anthonymatomd of @sloan_kettering presented the efficacy and tolerability results of LOXO-305 in B-cell malignancies at #ASH20 Catch his VJHemOnc interview at: 👉ow.ly/BKks50CELmM👈 ASH #HemOnc #Leusm #Leukemia #CLLsm #Lymsm #Lymphoma #CTsm #TrialUpdate

@UjjaniC Matthew Davids, MD, MMSc @SeattleCCA Georgetown Lombardi JTCancerCenter Dr. Catherine Lai Lori Leslie Mazyar Shadman, MD MPH Ryan Lynch Women in Lymphoma - [email protected] A good example of a context where a BH3 mimetic had modest single agent clinical activity (ironic in FL given t(14;18)) that looks to have combination utility.

Dr. Leslie, Lori Leslie, discusses "Clinical Outcomes Among Real-World Patients with CLL Initiating First-Line Ibrutinib or CIT Stratified By Risk Status: Results from a US Retrospective Chart Review Study." Learn More: buff.ly/3ha8yli

First-line #ibrutinib vs chemoimmunotherapy for #CLL w/ Lori Leslie of Mountainside Medical Center: ow.ly/PrJ350D39hf VJHemOnc #ASH20 #HemOnc #Leusm #Leukemia #RealWorldData #ImmunoOnc ASH #CLLsm

Thanks VJHemOnc for highlighting this ash presentation and the importance of testing for predictive/prognostic features prior to starting 1L treatment in CLL JTCancerCenter Mountainside Medical Center

fda.gov/drugs/drug-app… another exciting day for marginal zone and follicular lymphoma #lysm TG Therapeutics

cancernetwork.com/view/liso-cel-… and an exciting day for dlbcl #lysm. despite #COVID19 pandemic, #CancerResearch continues full force with a continued explosion of new #lymphoma treatment approvals.

Join me 2/27 to hear about Up-Front Therapy in iNHL and numerous other hot heme malignancy topics PER's “25th Annual International Congress on heme Malignancies®”. Register at: bit.ly/35UltUj #gotoHEM, earn CME, 35% discount on registration use code HEM21LL

Fda approval for yescarta in follicular is here! Thankful for our patients who participated, and grateful to be part of the Zuma5 team (marginal zone still open - mzl you’re next!) #lysm #cart #zuma5 Kite, a Gilead Company

Cant wait for a case-based CLL sequencing discussion with @anthonymatomd, Dr Barrientos Northwell Health & Dr Ferrajoli @LeukemiaMDA this thurs evening - want to join us? PER's upcoming Mentors in Medicine Series webcast on April 22. Register now: bit.ly/3wi03eN

WATCH NOW: @anthonymatomd, MD, MSCE, of @sloan_kettering and Lori Leslie, MD, of @HackensackUMC discuss differences in patient presentation and diagnosis of different types of indolent NHLs such as MZL & follicular lymphoma. #lymsm ow.ly/NPcT50Evkj9

fantastic news for patients with high risk DLBCL in 1st relapse #lymsm #CARTcell #lymphoma businesswire.com/news/home/2021…

ZUMA5 published 12/8 @LancetOncol authors.elsevier.com/c/1eD8W_XRRTqd… Efficacy durable with long term fu update presented at #ASH2021 today bit.ly/3oeDVjw. In FL ORR 94% (CR 79%) & with med fu 30.9 mo, 68% of CR in ongoing response. @MunshiPashna JTCancerCenter Hackensack Meridian School of Medicine

Paradigm shift for high risk DLBCL in 1st relapse. Join me Sunday 12/12/21 #ASH2021 for the #plenary session - ZUMA-7 study being presented with NEJM publication released today. I am just so incredibly happy for our pts. bit.ly/3Dc9EGh JTCancerCenter Hackensack Meridian School of Medicine

Andrew Ip, MD, explains the major toxicities of CAR T-cell therapy in patients with large B-cell lymphoma and how to manage them. #lymsm | Dr. Andre Goy Lori Leslie ow.ly/G65u50Kz7wR

Join us 11/2022 to celebrate the 40th anniversary of CFS where we will discuss the hottest topics in oncology and practice-changing strategies. Register now for 35% off with code: CFS22LL35 bit.ly/3OdCITO #gotoPER #hem #GoToCFS #lymsm

We love leukemia/lymphoma society !! Join our JTCC team! Even if you aren't free to walk at the Light the Night event on 10/15/2022 in Verona NJ, you can still join the team (and the FUN). JTCancerCenter team page pages.lls.org/ltn/cran/Veron… 伊藤佑愛 Hackensack Meridian

Join my colleagues and I next week for the 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®! Register today and use code CFSFree for a free registration! app.ingo.me/q/n819c #GoToPER #CFS40 

Very proud of David Qualls on this collaborative work from 12 centers!! @gilles_salles Loretta J. Nastoupil, MD Paolo F. Caimi Jen Crombie Kami Maddocks Brad Kahl Lori Leslie J Abramson G Nowakowski J. Romancik Venkat Seshan - Proof that we do our best work together

We are excited to announce the #ASCO23 presentation of the primary Overall Survival analysis from ZUMA7 (axi-cel vs chemo/ASCT in patients with 2L) will be featured in a special clinical science symposium. See you in Chicago! #lymsm